BN 104
Alternative Names: BN-104; BNM-1192Latest Information Update: 15 Feb 2024
At a glance
- Originator BioNova Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Menin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 15 Feb 2024 BN 104 receives Fast track status from the US FDA for Acute leukemia (Second-line therapy or greater) (greater) (BioNova Pharmaceuticals pipeline, February 2024)
- 15 Feb 2024 National Medical Products Administration (NMPA) approves IND application for BN 104 in Acute leukaemia (Second-line therapy or greater) (BioNova Pharmaceuticals pipeline, February 2024)
- 25 Sep 2023 BioNova Pharmaceuticals plans a phase I/II trial for Acute myeloid leukaemia and Precursor cell lymphoblastic leukaemia lymphoma (Second-line therapy or greater) (PO) in October 2023 (NCT06052813)